Dopamine D1 receptor expression in human basal ganglia and changes in Parkinson's disease

被引:50
|
作者
Hurley, MJ
Mash, DC
Jenner, P
机构
[1] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA
[2] Kings Coll London, Guys Kings & St Thomas Sch Biomed Sci, Neurodegenerat Dis Res Ctr, London SE1 1UL, England
来源
MOLECULAR BRAIN RESEARCH | 2001年 / 87卷 / 02期
关键词
basal ganglia; dopamine D-1 receptor; Parkinson's disease; radioligand binding; RT-PCR;
D O I
10.1016/S0169-328X(01)00022-5
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The expression of the human dopamine D-1 receptor was examined by reverse transcription polymerase chain reaction (RT-PCR) and radioligand binding using [H-3]-SCH23390 in post-mortem brain tissue that was obtained from normal subjects and patients dying with Parkinson's disease who were receiving treatment with dopaminergic drugs. D-1 receptor mRNA and specific [H-3]-SCH23390 binding sites were found in both striatal (nucleus accumbens, caudate nucleus and putamen) and extrastriatal (globus pallidus and substantia nigra) brain regions. In parkinsonian brain, D-1 receptor mRNA was increased in the nucleus accumbens, while a decrease was detected in the substantia nigra pars compacta. No change in D-1 mRNA levels was found in the other brain areas examined. An increase in the density of specific [H-3]-SCH23390 binding sites was found in the anterior putamen and a decrease in the external segment of the globus pallidus, no changes were detected elsewhere. This study demonstrates that regulation of D-1 receptor expression in the brain of patients dying with Parkinson's disease that were treated with L-DOPA is confined to small alterations in restricted brain regions. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:271 / 279
页数:9
相关论文
共 50 条
  • [21] Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain
    Hurley, MJ
    Mash, DC
    Jenner, P
    JOURNAL OF NEURAL TRANSMISSION, 2003, 110 (11) : 1279 - 1288
  • [22] Basal ganglia, dopamine and temporal processing: Performance on three timing tasks on and off medication in Parkinson's disease
    Jones, Catherine R. G.
    Malone, Tim J. L.
    Dirnberger, Georg
    Edwards, Mark
    Jahanshahi, Marjan
    BRAIN AND COGNITION, 2008, 68 (01) : 30 - 41
  • [23] From symphony to cacophony: Pathophysiology of the human basal ganglia in Parkinson disease
    Gale, John T.
    Amirnovin, Ramin
    Williains, Ziv M.
    Flaherty, Alice W.
    Eskandar, Emad N.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2008, 32 (03) : 378 - 387
  • [24] MULTIPLE FREQUENCIES IN THE BASAL GANGLIA IN PARKINSON'S DISEASE
    Davidson, Clare M.
    De Paor, Annraoi M.
    Lowery, Madeleine M.
    ADVANCES IN ELECTRICAL AND ELECTRONIC ENGINEERING, 2015, 13 (03) : 242 - 247
  • [25] Basal ganglia modulation of thalamocortical relay in Parkinson's disease and dystonia
    Guo, Yixin
    Park, Choongseok
    Worth, Robert M.
    Rubchinsky, Leonid L.
    FRONTIERS IN COMPUTATIONAL NEUROSCIENCE, 2013, 7
  • [26] Stereotactic microdialysis of the basal ganglia in Parkinson's disease
    Zsigmond, Peter
    Dernroth, Nezirevie
    Kullman, Anita
    Augustinsson, Lars-Erik
    Dizdar, Nil
    JOURNAL OF NEUROSCIENCE METHODS, 2012, 207 (01) : 17 - 22
  • [27] Role of HCN channels in the functions of basal ganglia and Parkinson's disease
    Qi, Zeng-Xin
    Yan, Qi
    Fan, Xiu-Juan
    Peng, Jian-Ya
    Zhu, Hui-Xian
    Jiang, Yi-Miao
    Chen, Liang
    Zhuang, Qian-Xing
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2024, 81 (01)
  • [28] Correlation transfer from basal ganglia to thalamus in Parkinson's disease
    Reitsma, Pamela
    Doiron, Brent
    Rubin, Jonathan
    FRONTIERS IN COMPUTATIONAL NEUROSCIENCE, 2011, 5
  • [29] Functional organization of the basal ganglia:: Therapeutic implications for Parkinson's disease
    Obeso, Jose A.
    Cruz Rodriguez-Oroz, Maria
    Benitez-Temino, Beatriz
    Blesa, Franscisco J.
    Guridi, Jorge
    Marin, Concepcio
    Rodriguez, Manuel
    MOVEMENT DISORDERS, 2008, 23 : S548 - S559
  • [30] Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease
    Bezard, Erwan
    Gray, David
    Kozak, Rouba
    Leoni, Matthew
    Combs, Cari
    Duvvuri, Sridhar
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2024, 23 (04) : 476 - 487